Side effects that have been reported with VONVENDI include: nausea, vomiting, tingling or burning at infusion site, chest discomfort, dizziness, hot flashes, itching, high blood pressure, muscle twitching, unusual taste, blood clots, and increased heart rate. Tell your healthcare provider about any side effects that bother you or do not go away.1
Safety evaluated in four prospective, multicenter trials1
Three studies were conducted in subjects with von Willebrand disease (VWD) and one was conducted in subjects with hemophilia A. The adverse reactions reported in the three VWD trials, with a total of 80 participants, are listed below.1
Side effects (most common to least common)
3.75% of participants (3 out of 80) experienced:
Dizziness
Nausea
Vomiting
2.5% of participants (2 out of 80) experienced:
Itching
Vertigo
1.25% of participants (1 out of 80) experienced:
Chest discomfort
Deep vein thrombosis (blood clots)
Hot flush
Hypertension
Increased heart rate
Tingling or burning at infusion site
Tremor
Unusual taste
Of the 125 total adverse events observed during the study, 8 (6.4%) were considered to have a causal relationship to VONVENDI.2
These are not all the possible side effects with VONVENDI. You can ask your healthcare provider for information that is written for healthcare professionals. Tell your healthcare provider about any side effects that bother you or do not go away.
On-demand efficacy
A clinical trial tested VONVENDI in adults for on-demand use.1
We use cookies to ensure that we give you the best experience possible. By continuing to browse this site, you are agreeing to our use of cookies as set out in our cookie notice. For more information on the cookies we use and how to delete or block the use of cookies, read our cookie policy.
VONVENDI is used in adults (age 18 years and older) diagnosed with von Willebrand disease to:
treat and control bleeding episodes
prevent excessive bleeding during and after surgery
Who should not use VONVENDI?
You should not use VONVENDI if you:
Are allergic to any ingredients in VONVENDI
Are allergic to mice or hamsters
References
VONVENDI Prescribing Information
Gill JC, Giancarlo C, Windyga J, et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 2015;126(17):2038-2045.
You're now leaving this site
Takeda does not review, endorse, or control the content of any non-Takeda site. Takeda is not responsible for the accuracy, content, practices, or standards of any non-Takeda resources accessed through a link on this site.